Yes, the orphan drug designation will get some some revenue, not sure how they will get the ASD component monetized though, I assume we would require a larger sample size to get this moving and it would be costly.
- Forums
- ASX - By Stock
- Ann: Phase II/III autism trial shows further benefits
Yes, the orphan drug designation will get some some revenue, not...
Featured News
Add NTI (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.8¢ |
Change
-0.003(3.70%) |
Mkt cap ! $79.35M |
Open | High | Low | Value | Volume |
8.2¢ | 8.2¢ | 7.8¢ | $91.06K | 1.149M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 43135 | 7.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.9¢ | 76163 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 12000 | 0.078 |
3 | 120000 | 0.077 |
2 | 107894 | 0.076 |
3 | 263338 | 0.075 |
3 | 260500 | 0.074 |
Price($) | Vol. | No. |
---|---|---|
0.080 | 125558 | 2 |
0.082 | 85000 | 1 |
0.086 | 100000 | 2 |
0.087 | 15209 | 1 |
0.088 | 208000 | 2 |
Last trade - 14.09pm 19/07/2024 (20 minute delay) ? |
Featured News
NTI (ASX) Chart |